Academic literature on the topic 'Anti-neutrophil cytoplasm antibody'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-neutrophil cytoplasm antibody.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Anti-neutrophil cytoplasm antibody"
Hewins, Peter, and Caroline Savage. "Anti-neutrophil cytoplasm antibody associated vasculitis." International Journal of Biochemistry & Cell Biology 35, no. 3 (March 2003): 277–82. http://dx.doi.org/10.1016/s1357-2725(02)00094-8.
Full textHolle, J. U. "ANCA („anti-neutrophil cytoplasm antibody“)-assoziierte Vaskulitiden." Zeitschrift für Rheumatologie 72, no. 5 (June 2013): 445–56. http://dx.doi.org/10.1007/s00393-013-1211-0.
Full textNAGASAWA, TOSHIHIKO. "Anti-blood neutrophil cytoplasm antibody (ANCA) and glomerulonephritis." Nihon Naika Gakkai Zasshi 83, no. 12 (1994): 2173–78. http://dx.doi.org/10.2169/naika.83.2173.
Full textSalama, A. D., and A. J. Rees. "Autoantibodies in anti-neutrophil cytoplasm antibody-associated vasculitis." Nephrology Dialysis Transplantation 29, no. 6 (January 23, 2014): 1105–7. http://dx.doi.org/10.1093/ndt/gft526.
Full textFerraro, Alastair J., Basma Hassan, and Caroline O. Savage. "Pathogenic mechanisms of anti-neutrophil cytoplasm antibody-associated vasculitis." Expert Review of Clinical Immunology 3, no. 4 (July 2007): 543–55. http://dx.doi.org/10.1586/1744666x.3.4.543.
Full textSalama, Alan D. "Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis." Kidney International Reports 5, no. 1 (January 2020): 7–12. http://dx.doi.org/10.1016/j.ekir.2019.10.005.
Full textMcAdoo, S. P., C. Densem, A. Salama, and C. D. Pusey. "Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody." Clinical Kidney Journal 4, no. 3 (April 2, 2011): 208–10. http://dx.doi.org/10.1093/ndtplus/sfr030.
Full textYOSHIDA, Masaharu, Motoaki SAITO, and Toshihiko NAGASAWA. "Studies on anti-neutrophil cytoplasm antibody(ANCA) in Wegener's granulomatosis." Nihon Naika Gakkai Zasshi 78, no. 11 (1989): 1581–85. http://dx.doi.org/10.2169/naika.78.1581.
Full textJones, Rachel B. "Rituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis." Nephron Clinical Practice 128, no. 3-4 (November 14, 2014): 243–49. http://dx.doi.org/10.1159/000368580.
Full textChapman, Gavin B., Andrew E. Leitch, Rashmi Lahiri, Peter Reid, and Neeraj Dhaun. "Strawberry carina as a presentation of anti-neutrophil cytoplasm antibody–associated vasculitis." Rheumatology 61, no. 3 (October 20, 2021): e59-e61. http://dx.doi.org/10.1093/rheumatology/keab783.
Full textDissertations / Theses on the topic "Anti-neutrophil cytoplasm antibody"
Pankhurst, Tanya. "Heterogeneity of injury in vasculitis : influence of anti neutrophil cytoplasm antibody IgG subclass and endothelial susceptibility." Thesis, University of Birmingham, 2010. http://etheses.bham.ac.uk//id/eprint/718/.
Full textDurant, Stéphanie. "Etude moléculaire et fonctionnelle de la protéinase 3 du neutrophile, cible des ANCA : implications physiopathologiques dans les vascularites." Paris 6, 2003. http://www.theses.fr/2003PA066526.
Full text李瑞山 and Shui-shan Lee. "Anti-neutrophil cytoplasmic antibody: a clinical & experimental study." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1993. http://hub.hku.hk/bib/B31981513.
Full textLee, Shui-shan. "Anti-neutrophil cytoplasmic antibody : a clinical & experimental study /." [Hong Kong : University of Hong Kong], 1993. http://sunzi.lib.hku.hk/hkuto/record.jsp?B13762679.
Full textRajp, Amit. "The immunogenetics of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis." Thesis, University of Birmingham, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273729.
Full textBansi, Devinder Singh. "Immunologyical mechanisms in primary primary sclerosing cholangitis : the role of the anti-neutrophil cytoplasmic antibody." Thesis, University of Southampton, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.242304.
Full textGovender, Ramona. "Anti-neutrophil cytoplasmic antibody (ANCA) testing at Groote Schuur Hospital: Adherence to indications for testing." Master's thesis, Faculty of Health Sciences, 2021. http://hdl.handle.net/11427/33700.
Full textBasu, Neil. "The characterisation and determinants of quality of life in ANCA associated vasculitis." Thesis, University of Aberdeen, 2012. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=189406.
Full textBensalem, Amina. "Pharmacocinétique et relation dose-concentration-effet du rituximab dans la polyartrite rhumatoïde et les vascularités associées aux anticorps anti-cytoplasme des neutrophiles." Thesis, Tours, 2019. http://www.theses.fr/2019TOUR3302.
Full textRituximab is a chimeric IgG1 monoclonal antibody (mAb) that targets CD20, a protein on the surface of most B lymphocytes. It is approved as a second line treatment in rheumatoid arthritis (RA) patients, and is used in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There is a large interindividual variability in rituximab pharmacokinetics (PK), and its concentration–response relationship. Rituximab binds to CD20 with high affinity and specificity and form mAb-target complexes which are eliminated by immune system. This elimination is usually described using target-mediated drug disposition (TMDD) models. For rituximab, TMDD was never reported in autoimmune inflammatory diseases, as RA or AAV. This PhD work aimed at studying the variability of PK and cconcentration-response relationship of rituximab using population PK and pharmacokinetic-pharmacodynamic (PK-PD) modeling. This work was done using data from : - 52 RA patients of the rheumatology department of Tours University Hospital, where rituximab concentrations, CD4+ counts (biomarker) and disease activity score in 28 joints (DAS28, clinical response) were measured. - 92 AAV patients included in the RAVE trial (Rituximab for AAV), where rituximab concentrations, antibodies to proteinase 3 (PR3-ANCA), and antibodies to myeloperoxidase (MPO-ANCA) (biomarkers) were measured. In RA patients, rituximab PK was described using a two-compartment model with linear (endogenous) elimination. No target-elimination of rituximab or influence of B-cell count was detected. This may be due to (i) a low amount of target antigen compared to B-cell neoplasia, and/or (ii) insufficiently dense PK data. In AAV patients, nonlinear target-mediated elimination was detected at the beginning of the follow-up. A simplified TMDD model was used, where target was modeled as a latent variable, and irreversible binding to rituximab on its target was assumed. Latent variable may be partly interpreted as the fraction of CD20 (circulating or present at the B-cell membrane) available for rituximab binding. The negligible target-mediated elimination towards the end of the follow-up in RA and AAV may be due to the sustained B-cell depletion after rituximab treatment. Rituximab-induced B cell depletion was shown to alter count and function of other immune cells. However, quantitative relationship between depletion of blood B cells, immune cells, and clinical response in both RA and AAV remain unclear. In addition, this relationship, highly variable among patients, was never quantified using PK-PD modeling. In RA patients, the relationship between rituximab concentrations and CD19+ counts, between CD19+ and CD4+ counts, and between CD4+ counts and DAS28 (clinical activity score in RA) was described using cell lifespan, indirect response and direct Emax models, respectively. This study showed that (i) the amplitude of CD19+ count depletion was not associated with CD4+ decrease or DAS28, and (ii) CD4+ decrease leads to two-fold DAS28 decrease compared to no CD4+ decrease, and (iii) higher rituximab concentrations were related to a better clinical improvement. In AAV patients, the relationship between rituximab concentrations and ANCA levels was described using a semi-mechanistic transit model with negative feedback. This model showed that (i) rituximab-induced decrease of ANCA levels was deep but delayed, and more sustained in patients with MPO-ANCA than in those with PR3-ANCA, and (ii) higher rituximab concentrations were associated with deeper decrease of ANCA levels. Moreover, repeated rituximab courses may improve clinical response to rituximab, and increase the time to disease relapse. Overall, this work was the first to report nonlinear PK of rituximab in autoimmune disease (AAV), and to quantify the complex relationship between rituximab-induced B-cell depletion, CD4+ decrease, and the clinical response
Tieu, Joanna. "Optimising Management in ANCA-Associated Vasculitis." Thesis, 2021. https://hdl.handle.net/2440/135593.
Full textThesis (Ph.D.) -- University of Adelaide, Adelaide Medical School, 2022
Books on the topic "Anti-neutrophil cytoplasm antibody"
Sinico, Renato Alberto, and Loïc Guillevin, eds. Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-02239-6.
Full textRajp, Amit. The immunogenetics of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Birmingham: University of Birmingham, 2002.
Find full textGuillevin, Loïc, and Renato Alberto Sinico. Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis. Springer, 2019.
Find full textGross, Wolfgang L., and Julia U. Holle. Clinical features of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0131.
Full textFoster, Helen, and Paul A. Brogan, eds. Systemic diseases. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199592630.003.0004.
Full textJayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.
Full textTombetti, Enrico, and Justin C. Mason. Pathophysiology of vasculitis. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755777.003.0017.
Full textBook chapters on the topic "Anti-neutrophil cytoplasm antibody"
Selvakumar, Vijayalakshmi, Thenmozhi Manivel, Ramachandran Chelliah, Kaliyan Barathikannan, Akanksha Tyagi, Xiuqin Chen, Umair Shabbir, et al. "Microorganisms in Pathogenesis and Management of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis." In Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases, 311–39. Singapore: Springer Nature Singapore, 2022. http://dx.doi.org/10.1007/978-981-19-4800-8_16.
Full textBoomsma, Maarten M., Coen A. Stegeman, Cees G. M. Kallenberg, and Jan W. Cohen Tervaert. "Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: the role for autoantibody guided and anti-bacterial treatment." In Disease-modifying Therapy in Vasculitides, 181–99. Basel: Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8235-4_10.
Full textGross, Wolfgang L., and Julia U. Holle. "Clinical features of ANCA-associated vasculitis." In Oxford Textbook of Rheumatology, 1090–102. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0131_update_001.
Full textChung, Sharon, and Paul A. Monach. "Anti-neutrophil Cytoplasmic Antibody–Associated Vasculitis." In Kelley and Firestein's Textbook of Rheumatology, 1541–58. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-323-31696-5.00089-9.
Full textJayne, David. "Treatment of ANCA-associated vasculitis." In Oxford Textbook of Rheumatology, 1103–12. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132_update_001.
Full textVuković Brinar, Ivana, and Matija Matošević. "Complement-Mediated Kidney Disease." In Novel Topics in the Diagnosis, Treatment, and Follow-Up of Nephritis, Nephrotic Syndrome, and Nephrosis [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.108555.
Full textConference papers on the topic "Anti-neutrophil cytoplasm antibody"
Chopra, M., and E. Cristan. "Rivaroxaban Induced Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4953.
Full textFidler, L., S. Kandel, J. H. Fisher, S. Mittoo, and S. Shapera. "Anti-Neutrophil Cytoplasmic Antibody Screening in Idiopathic Interstitial Lung Disease." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3367.
Full textMulleman, Denis, Amina Bensalem, David Ternant, Gilles Paintaud, Divi Cornec, and Ulrich Specks. "THU0309 NONLINEAR PHARMACOKINETICS OF RITUXIMAB IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4897.
Full textNakagawa, Naoko, Yoshinori Tanino, Yayoi Inokoshi, Kazue Saito, Taeko Ishii, Takefumi Nikaido, Atsuro Fukuhara, et al. "Clinical Analysis Of Anti-Neutrophil Cytoplasmic Antibody In Patients With Interstitial Pneumonia." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6006.
Full textNakahara, M., H. Yamashita, Y. Takahashi, K. Araki, N. Mino, K. Suga, A. Yashima, and H. Kaneko. "AB0682 Risk factors associated with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5468.
Full textKaghazian, M., C. W. Akabusi, K. P. Acosta, K. Kallakuri, and P. Shakouri. "Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis Secondary to Pfizer-BioNTech COVID-19 Vaccine." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1384.
Full textBensalem, Amina, David Ternant, Nicolas Azzopardi, Gilles Paintaud, Valérie Gouilleux-Gruart, Divi Cornec, Ulrich Specks, and Denis Mulleman. "SAT0236 RELATIONSHIP BETWEEN RITUXIMAB CONCENTRATION AND AUTOANTIBODY LEVELS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7552.
Full textAntovic, A., M. Kostic, F. Mobarrez, A. Nordin, J. Vojinovic, A. Bruchfeld, and I. Gunnarsson. "OP0052 Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody – associated vasculitis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5465.
Full textShah, R., R. Trachtman, B. Coakley, and A. Vicencio. "A Rare Case of Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody Double Positive Disease in a Preschool-Aged Child." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3264.
Full textKobayashi, K., D. Nakagomi, S. Hanai, M. Yamagata, T. Sugiyama, H. Kawashima, M. Hiraguri, et al. "AB0676 Efficacy of rituximab therapy against anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis: a case series." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5345.
Full text